NLS Pharmaceutics (NLSP.Q) Announces FDA Acceptance to Initiate Quilience® Clinical Trials

NLS Pharmaceutics (NLSP.Q) announced today that the U.S. Food and Drug Administration (FDA) has accepted its Investigational New Drug (IND) application for Quilience® extended release, the Company’s lead drug candidate for the treatment of narcolepsy.

Read full article here: https://equity.guru/2021/07/nls-pharmaceutics-nlsp-q-announces-fda-acceptance-to-initiate-quilience-clinical-trials/